Citations 2
Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.
Pitot, Henry C., Hurwitz, Herbert I. , Zanna, Claudio , Brill, Jeffrey Mark, Vuagniaux, Grégoire, Rouits, Elisabeth , Sorensen, John M., Smith, David C.
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2531-2531
First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results.
Hurwitz, Herbert I. , Pitot, Henry C., Smith, David C. , Brill, Jeffrey Mark, Vuagniaux, Grégoire, Rouits, Elisabeth , Zanna, Claudio , Sorensen, John M.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2532-2532